Overview

Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders

Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The study objective is to explore the safety and tolerability of STX209 in subjects with Autism Spectrum Disorders and to obtain preliminary data on several measures of efficacy in treating irritability. We hypothesize that STX209 will be safe and well-tolerated.
Phase:
Phase 2
Details
Lead Sponsor:
Seaside Therapeutics, Inc.